Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamic and Pharmacokinetic Study of PL-ASA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female non-smoking subjects between the ages of 18 to 75 years inclusive, without known medical conditions requiring treatment~* Consumes on average no more than 2 alcoholic drinks per day for 30 days prior to study~Exclusion Criteria:~* Abnormal baseline laboratory results~* Current prescribed use of aspirin, warfarin or other anticoagulants~* Use of other specific medications within 2 weeks of study start~* History of certain medical conditions~* Subject's platelets are unresponsive to arachidonic acid, as defined as \<60% of aggregation as measured by light transmittance aggregometry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- PL-ASA capsule, then EC-ASA tablet (Type: OTHER): PL-ASA capsule 81 mg, then crossover to EC-ASA tablet 81 mg
- EC-ASA tablet, then PL-ASA capsule (Type: ACTIVE_COMPARATOR): EC-ASA tablet 81 mg, then crossover to PL-ASA capsule 81 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).